A meta-analysis of the impact of human leukocyte antigen-G on the outcomes of IVF/ICSI

Niu, Ziru; Wang, Liangyi; Pang, Ronald T.K.; Guo, Yifan; Yeung, William Shu Biu; Yao, Yuanqing

doi:10.1016/j.rbmo.2017.03.002

Cited by 18 publications

(34 citation statements)

References 40 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is the first meta-analysis including a global data analysis of all disease association studies already published focusing the HLA-G 14bp polymorphism as target. As previously mentioned, the others available meta-analyses evaluated this 3′UTR gene variability focusing on only one disease [14][15][16][17][18][19][20][21][22]151] or a small group of diseases [23][24][25]. Considering the meta-analysis performed in the present studied, we can conclude that, although 14-bp HLA-G 3′UTR polymorphism is an easily detected variation site widely used in disease association studies, this polymorphism cannot be used as a sole genetic marker for disease susceptibility.…”

Section: Respectivelymentioning

confidence: 58%

Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Respectivelymentioning

confidence: 58%

Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In accordance, Diaz et al 89 reported significantly higher levels of sHLA‐G secretion in embryos resulted in pregnancy compared to those of unsuccessful pregnancy (28.0 ± 18.8 vs. 19.0 ± 17.6 unit/ml). More interestingly, in a meta‐analysis study conducted by Niu et al, 90 it has been revealed that embryo culture media with sHLA‐G positively associated with implantation (OR: 2.66, CI: 95%, p < .00001) and clinical pregnancy (OR: 3.79, CI: 95%, p < .00001) rates compared with those without. They concluded that the presence of sHLA‐G in the embryo culture medium paves the way for higher implantation and pregnancy rates.…”

Section: Embryo‐secreted Non‐cytokines As Markers For Embryo Selectiomentioning

confidence: 96%

Cytokines in embryonic secretome as potential markers for embryo selection

Bahrami-Asl

Hajipour

Rezaei

et al. 2020

American J Rep Immunol

View full text Add to dashboard Cite

Despite performing certain morphological assessments for selecting the best embryo for transfer, the results have not been satisfactory. Given the global tendency for performing quick and noninvasive tests for embryo selection, great efforts have been made to discover the predictive biomarkers of embryo implantation potential. In recent years, many factors have been detected in embryo culture media as a major source of embryo secretions. Previous studies have evaluated cytokines, miRNAs, extracellular vesicles, and other factors such as leukemia inhibitory factor, colony‐stimulating factor, reactive oxygen species, soluble human leukocyte antigen G, amino acids, and apolipoproteins in these media. Given the key role of cytokines in embryo implantation, these factors can be considered promising molecules for predicting the implantation success of assisted reproductive technology (ART). The present study was conducted to review embryo‐secreted molecules as potential biomarkers for embryo selection in ART.

show abstract

“…However, these data are still preliminary and a multicenter study demonstrated widely differing results [113]. Moreover, a recently published meta-analysis demonstrates the opposite: the presence of soluble HLA-G in the culture medium results in higher implantation and pregnancy rates [114]. Unfortunately, there is no information which soluble HLA-G isoforms were measured—G5, G6, or G7.…”

Section: Interaction Of Hla-e To -G With Receptor Families Of Immumentioning

confidence: 99%

European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment

Würfel¹,

Winterhalter²,

Trenkwalder³

et al. 2019

IJMS

View full text Add to dashboard Cite

The granted European patent EP 2 561 890 describes a procedure for an immunological treatment of cancer. It is based on the principles of the HLA-supported communication of implantation and pregnancy. These principles ensure that the embryo is not rejected by the mother. In pregnancy, the placenta, more specifically the trophoblast, creates an “interface” between the embryo/fetus and the maternal immune system. Trophoblasts do not express the “original” HLA identification of the embryo/fetus (HLA-A to -DQ), but instead show the non-classical HLA groups E, F, and G. During interaction with specific receptors of NK cells (e.g., killer-immunoglobulin-like receptors (KIR)) and lymphocytes (lymphocyte-immunoglobulin-like receptors (LIL-R)), the non-classical HLA groups inhibit these immunocompetent cells outside pregnancy. However, tumors are known to be able to express these non-classical HLA groups and thus make use of an immuno-communication as in pregnancies. If this occurs, the prognosis usually worsens. This patent describes, in a first step, the profiling of the non-classical HLA groups in primary tumor tissue as well as metastases and recurrent tumors. The second step comprises tailored antibody therapies, which is the subject of this patent. In this review, we analyze the underlying mechanisms and describe the currently known differences between HLA-supported communication of implantation and that of tumors.

show abstract

A meta-analysis of the impact of human leukocyte antigen-G on the outcomes of IVF/ICSI

Cited by 18 publications

References 40 publications

Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis

Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis

Cytokines in embryonic secretome as potential markers for embryo selection

European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment

Contact Info

Product

Resources

About